BR112014029642A2 - composto, combinação de um composto, composição farmacêutica, uso de um composto, dispositivo e kit - Google Patents

composto, combinação de um composto, composição farmacêutica, uso de um composto, dispositivo e kit

Info

Publication number
BR112014029642A2
BR112014029642A2 BR112014029642A BR112014029642A BR112014029642A2 BR 112014029642 A2 BR112014029642 A2 BR 112014029642A2 BR 112014029642 A BR112014029642 A BR 112014029642A BR 112014029642 A BR112014029642 A BR 112014029642A BR 112014029642 A2 BR112014029642 A2 BR 112014029642A2
Authority
BR
Brazil
Prior art keywords
compound
kit
combination
pharmaceutical composition
pharmaceutical
Prior art date
Application number
BR112014029642A
Other languages
English (en)
Inventor
Capaldi Carmelida
Aarmani Elisabetta
Carzaniga Laura
Esposito Oriana
Original Assignee
Chiesi Farm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farm Spa filed Critical Chiesi Farm Spa
Publication of BR112014029642A2 publication Critical patent/BR112014029642A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
BR112014029642A 2012-06-04 2013-05-28 composto, combinação de um composto, composição farmacêutica, uso de um composto, dispositivo e kit BR112014029642A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12170714 2012-06-04
PCT/EP2013/060915 WO2013182451A1 (en) 2012-06-04 2013-05-28 Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors

Publications (1)

Publication Number Publication Date
BR112014029642A2 true BR112014029642A2 (pt) 2017-06-27

Family

ID=48670496

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014029642A BR112014029642A2 (pt) 2012-06-04 2013-05-28 composto, combinação de um composto, composição farmacêutica, uso de um composto, dispositivo e kit

Country Status (11)

Country Link
US (1) US9440954B2 (pt)
EP (1) EP2855450B1 (pt)
KR (1) KR20150022789A (pt)
CN (1) CN104334542A (pt)
AR (1) AR091261A1 (pt)
BR (1) BR112014029642A2 (pt)
CA (1) CA2875421A1 (pt)
HK (1) HK1205116A1 (pt)
IN (1) IN2014DN10239A (pt)
RU (1) RU2637945C2 (pt)
WO (1) WO2013182451A1 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2022783A1 (en) 2007-08-08 2009-02-11 CHIESI FARMACEUTICI S.p.A. "Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors"
EP2216327A1 (en) 2009-02-06 2010-08-11 CHIESI FARMACEUTICI S.p.A. Benzoic acid (1-phenyl-2-pyridin-4-yl)ethyl esters as phosphodiesterase inhibitors
CN103562185A (zh) * 2011-06-06 2014-02-05 奇斯药制品公司 作为磷酸二酯酶抑制剂的1-苯基-2-吡啶基烷基醇的衍生物
CN103827088B (zh) 2011-09-26 2017-10-13 奇斯药制品公司 作为磷酸二酯酶抑制剂的1‑苯基‑2‑吡啶基烷基醇的衍生物
BR112015012716A2 (pt) 2012-12-05 2017-07-11 Chiesi Farm Spa derivados de feniletilpiridina como inibidores de pde4
CN104837828B (zh) 2012-12-05 2017-07-18 奇斯药制品公司 作为pde4‑抑制剂的苯基乙基吡啶衍生物
AR093798A1 (es) 2012-12-05 2015-06-24 Chiesi Farm Spa Compuestos
KR102192739B1 (ko) 2012-12-05 2020-12-18 키에시 파르마슈티시 엣스. 피. 에이. 포스포디에스테라제 억제제로서 1-페닐-2-피리디닐 알킬 알코올의 유도체
AR104829A1 (es) * 2015-06-01 2017-08-16 Chiesi Farm Spa Derivados de aminoésteres
AR104822A1 (es) * 2015-06-01 2017-08-16 Chiesi Farm Spa Derivado de aminoésteres
WO2020145250A1 (ja) 2019-01-08 2020-07-16 杏林製薬株式会社 15-pgdh阻害薬
CN116082670B (zh) * 2023-04-11 2023-06-27 中国人民解放军军事科学院军事医学研究院 一种含有季膦盐的声响应假性共轭聚合物纳米颗粒的制备方法及其在抗菌领域的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL307265A1 (en) 1992-07-28 1995-05-15 Rhone Poulenc Rorer Ltd Compounds containing a phenyl group bonded with aryl or heteroaryl group through their bonding aliphatic group or that containing heteroatom
US5786354A (en) 1994-06-21 1998-07-28 Celltech Therapeutics, Limited Tri-substituted phenyl derivatives and processes for their preparation
TW200420554A (en) 2003-03-31 2004-10-16 Kyowa Hakko Kogyo Kk A intra-airway administrating preparation
WO2008006509A1 (en) * 2006-07-14 2008-01-17 Chiesi Farmaceutici S.P.A. Derivatives of 1-phenyl-2-pyridynyl alkylene alcohols as phosphodiesterase inhibitors
MX2009009238A (es) * 2007-02-28 2009-09-08 Leo Pharma As Nuevos inhibidores de fosfodiesterasa.
EP2022783A1 (en) 2007-08-08 2009-02-11 CHIESI FARMACEUTICI S.p.A. "Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors"
EP2070913A1 (en) * 2007-12-14 2009-06-17 CHIESI FARMACEUTICI S.p.A. Ester derivatives as phosphodiesterase inhibitors
EP2110375A1 (en) 2008-04-14 2009-10-21 CHIESI FARMACEUTICI S.p.A. Phosphodiesterase-4 inhibitors belonging to the tertiary amine class
EP2216327A1 (en) 2009-02-06 2010-08-11 CHIESI FARMACEUTICI S.p.A. Benzoic acid (1-phenyl-2-pyridin-4-yl)ethyl esters as phosphodiesterase inhibitors
CN103562185A (zh) 2011-06-06 2014-02-05 奇斯药制品公司 作为磷酸二酯酶抑制剂的1-苯基-2-吡啶基烷基醇的衍生物
CN103827088B (zh) 2011-09-26 2017-10-13 奇斯药制品公司 作为磷酸二酯酶抑制剂的1‑苯基‑2‑吡啶基烷基醇的衍生物
CN103889972A (zh) 2011-10-21 2014-06-25 奇斯药制品公司 作为磷酸二酯酶抑制剂的1-苯基-2-吡啶基烷基醇的衍生物

Also Published As

Publication number Publication date
EP2855450B1 (en) 2016-07-06
IN2014DN10239A (pt) 2015-08-07
RU2014148316A (ru) 2016-07-27
US20130324501A1 (en) 2013-12-05
WO2013182451A9 (en) 2014-02-06
CA2875421A1 (en) 2013-12-12
RU2637945C2 (ru) 2017-12-08
EP2855450A1 (en) 2015-04-08
CN104334542A (zh) 2015-02-04
KR20150022789A (ko) 2015-03-04
HK1205116A1 (en) 2015-12-11
US9440954B2 (en) 2016-09-13
WO2013182451A1 (en) 2013-12-12
AR091261A1 (es) 2015-01-21

Similar Documents

Publication Publication Date Title
BR112015000420A2 (pt) composto, composição farmacêutica, e, uso de um composto
BR112014029115A2 (pt) composto, composição farmacêutica, e, uso de um composto ou composição
BR112014001255A2 (pt) composto, uso de um composto, combinação, e, composição farmacêutica
BR112014029530A2 (pt) compostos, composição farmacêutica e uso de um composto
BR112014013760A2 (pt) composto, composição farmacêutica e uso de um composto
BR112013030302A2 (pt) composto, composição farmacêutica, uso de um composto, combinação de um composto e dispositivo
BR112013008259A2 (pt) composto, composição farmacêutica, e, uso de um composto
BR112014029642A2 (pt) composto, combinação de um composto, composição farmacêutica, uso de um composto, dispositivo e kit
BR112016003229A2 (pt) Composto, composição farmacêutica, e, uso de um composto ou de uma composição farmacêutica
CR20150380A (es) Compuestos de carbamoilpiridona policíclicos y su uso farmacéutico
BR112013015397A2 (pt) composto, composição farmacêutica, e, uso de um composto
BR112014005669A2 (pt) composto, composição farmacêutica e uso de um composto
BR112014000260A2 (pt) composto, e, uso de um composto
BR112014009471A2 (pt) compostos, combinação de um composto, composição farmacêutica, uso de um composto, dispositivo e kit
BR112014003567A2 (pt) composto, uso de um composto, e, composição farmacêutica
BR112014014547A2 (pt) compostos antagonistas de e-selectina, composições e métodos de uso
BR112015002738A2 (pt) composto , e , composição farmacêutica
BR112014023200A2 (pt) uso de uma composição
BR112012031226A2 (pt) composto, uso do composto, composição farmacêutica, e uso de composição farmacêutica
BR112013011448A2 (pt) composto, composição farnmacêutica, e, uso do composto
BR112014013177A2 (pt) composto, composição farmacêutica e uso de um composto
BR112014016635A2 (pt) composto, composição, e, uso de um composto
BR112013006016A2 (pt) compostos de azabenzotiazol, composições e métodos de uso
BR112015007310A2 (pt) compostos, composição farmacêutica, uso de um composto de fórmula (i) e uso de uma composição farmacêutica
BR112014013178A2 (pt) composto, composição farmacêutica e uso de um composto

Legal Events

Date Code Title Description
B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE A 4A ANUIDADE.

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)